Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma
Autore:
Allen, IE; Ross, SD; Borden, SP; Monroe, MW; Kupelnick, B; Connelly, JE; Ozer, H;
Indirizzi:
MetaWorks Inc, Medford, MA 02155 USA MetaWorks Inc Medford MA USA 02155MetaWorks Inc, Medford, MA 02155 USA Babson Coll, Wellesley, MA USA Babson Coll Wellesley MA USABabson Coll, Wellesley, MA USA Med Coll Penn & Hahnemann Univ, Ctr Canc, Philadelphia, PA USA Med Coll Penn & Hahnemann Univ Philadelphia PA USA Philadelphia, PA USA
Titolo Testata:
JOURNAL OF IMMUNOTHERAPY
fascicolo: 1, volume: 24, anno: 2001,
pagine: 58 - 65
SICI:
1524-9557(200101/02)24:1<58:MTATEO>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
RANDOMIZED CONTROLLED TRIALS; RECOMBINANT LEUKOCYTE; CLINICAL-TRIALS; LUNG-CANCER; CYCLOPHOSPHAMIDE; MAINTENANCE; SURVIVAL; PREDNIMUSTINE; METAANALYSIS; AUGMENTATION;
Keywords:
interferon; Non-Hodgkin's lymphoma meta-analysis; systematic review; survival;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Ross, SD MetaWorks Inc, 10 Presidents Landing, Medford, MA 02155 USA MetaWorks Inc 10 Presidents Landing Medford MA USA 02155 2155 USA
Citazione:
I.E. Allen et al., "Meta-analysis to assess the efficacy of interferon-alpha in patients with follicular non-Hodgkin's lymphoma", J IMMUNOTH, 24(1), 2001, pp. 58-65

Abstract

The authors wanted to determine whether adding interferon-alpha (IFN-alpha) to chemotherapy regimens, in either induction or maintenance settings, provides additional survival benefits in follicular non-Hodgkin's lymphoma (NnL). A meta-analysis was performed based on published data from randomized controlled clinical trials involving nine separate study populations. Patients receiving IFN-alpha (in either induction or maintenance therapy) had significantly increased 5-year and progression-free survival rates at 3 and 5years compared with concurrent controls. The advantages of IFN-alpha therapy were most marked in studies using anrhracycline-containing induction chemotherapy; in these studies, patients who received IFN-alpha had approximately 20% increased progression-free survival rates compared with controls and a lesser survival advantage. The available literature did not allow a determination of the relative benefit of IFN-alpha in induction or maintenancetreatments for NHL or a determination of the optimum duration of IFN-alphatreatment. Although questions remain about its optimal use, IFN-alpha appears to prolong survival time in patients with follicular NHL.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/02/20 alle ore 12:00:06